Larsmont-FA Tablet SR is a sustained-release formulation combining Montelukast (10mg), Fexofenadine (120mg), and Acebrophylline (200mg), designed for the management of respiratory conditions characterized by bronchoconstriction, inflammation, and allergic reactions. Montelukast, a leukotriene receptor antagonist, effectively reduces airway inflammation and bronchospasm by inhibiting leukotriene-mediated effects. Fexofenadine, a second-generation antihistamine, provides relief from allergic symptoms such as rhinorrhea, sneezing, and nasal congestion without causing significant sedation. Acebrophylline, a bronchodilator with mucolytic and anti-inflammatory properties, facilitates airway clearance by relaxing bronchial muscles and reducing mucus viscosity. The sustained-release formulation ensures prolonged therapeutic action, improving patient compliance by reducing dosing frequency. Larsmont-FA Tablet SR is indicated for the treatment of chronic bronchitis, asthma, allergic rhinitis, and other obstructive airway diseases where combined anti-inflammatory, bronchodilator, and antihistaminic effects are beneficial. It should be used under medical supervision, with caution in patients with hepatic or renal impairment. Common side effects may include headache, gastrointestinal disturbances, and mild dizziness. This combination therapy offers a comprehensive approach to managing respiratory symptoms, enhancing patient quality of life through multi-modal pharmacological action.